TKI Therapy Affects Quality of Life in CML Patients - Medscape
Jun 20, 2013 · TKI Therapy Affects Quality of Life in CML Patients. Roxanne Nelson. June 20, 2013. Patients with chronic myeloid leukemia (CML) who are being treated with tyrosine kinase inhibitors (TKIs) have ...
FDA Approves Osimertinib for Unresectable NSCLC - Medscape
Sep 27, 2024 · The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment of locally advanced, unresectable non–small cell lung cancer (NSCLC ...
Sequential Therapy in Metastatic Clear Cell Renal Carcinoma
Sequential therapy with either continued VEGF receptor inhibition (tyrosine kinase inhibitor [TKI]-TKI sequence) or alternate pathway inhibition (TKI–mTOR sequence) results in prolonged disease ...
Adjuvant TKI Therapy for Early-Stage EGFR Mutation-Positive NSCLC
Jul 7, 2017 · Adjuvant TKI Therapy for Early-Stage EGFR Mutation-Positive NSCLC: Is Disease-Free Survival Enough? H. Jack West, MD. Disclosures. July 07, 2017.
Treating Squamous Non-Small Cell Lung Cancer With EGFR TKI …
Jul 15, 2016 · Treating Squamous Non-Small Cell Lung Cancer With EGFR TKI Therapy. H. Jack West, MD. Disclosures. July 15, 2016 ...
ASCO Recommends EGFR Testing for NSCLC, But for Which …
Apr 28, 2011 · However, Dr. Keedy provided some insight to Medscape Medical News. "Patients typically considered for first-line EGFR TKI therapy are those who are never smokers or former light smokers," she ...
Episode 1: Chronic Myeloid Leukemia Therapy and the Mark
Jun 29, 2023 · Drs Michael J. Mauro and Hagop Kantarjian discuss the cost of chronic myeloid leukemia therapy, long-term safety, adverse events, and the financial toxicity to the patient and the healthcare system.
Aumolertinib Promising Maintenance Therapy in EGFR+ NSCLC
Sep 11, 2024 · Aumolertinib maintenance therapy led to a significant improvement in progression-free survival in unresectable, stage III, EGFR-mutated non–small cell lung cancer. This site is intended for ...
In NSCLC After Progression on First-line TKI, What Next? - Medscape
Sep 29, 2014 · The main message from the IMPRESS study is that after progression on first-line TKI therapy, the combination of chemotherapy plus TKI should not be used, especially as there was a suggestion of a ...
ASCO 2024: Advances in Targeted Therapy for Lung Cancer
Jul 1, 2024 · Those are the population post-EGFR TKI and the patients need chemo. The comparator arm is chemo, but the experimental is chemo plus a bispecific PD-L1 and VEGF. The study was positive and the ...